Biomay Launches Optimized Cas9 mRNA with Low dsRNA Content
Press release Vienna, Austria (March 17, 2026) Biomay announces the availability of an optimized mRNA-variant encoding the nuclease spCas9 featuring enhanced design and purity characteristics. The new product is immediately available in the quality grades GMP and RUO.
The Cas9 coding sequence is human codon-optimized, incorporates N1-methyl-pseudouridine (m1Ψ), and is flanked by human untranslated regions (UTRs) to support efficient translation. A well-established Cap1 structure is used as the 5′-cap. Characteristically, the molecule further contains a poly(A) tail of 145 adenosines, exceeding the length used in comparable products and thereby supporting improved mRNA stability and translational efficiency.
Importantly, as a result of continuous process intensification and many years of GMP manufacturing experience, Biomay’s Cas9 mRNA exhibits high purity and integrity. In particular, double-stranded RNA (dsRNA) – a key impurity generated during in-vitro mRNA transcription – is present at exceptionally low levels (dsRNA = 0.0005 % w/w). In addition, the product shows ultra-low endotoxin levels (< 0.2 EU/mg mRNA), high 5′-capping efficiency (> 95%), and high general integrity (> 90%).
Biomay’s Cas9 mRNA is produced using a fully integrated GMP manufacturing platform supported by a robust panel of validated analytical assays. Functional performance has been confirmed in cell-based assays, demonstrating equivalence to leading benchmark Cas9 mRNA products.
As an FDA-inspected manufacturer, Biomay is committed to delivering mRNA products of the highest quality standards, supporting clients from early research to clinical-stage programs. With this launch, Biomay further strengthens its position as a one-stop provider of mRNA based tools. Whether for early-stage research or clinical development, Biomay’s Cas9 mRNA provides reliability, quality, and speed – from a single trusted source.
About Biomay
Biomay AG is a fully integrated Contract Development and Manufacturing Organization (CDMO) based in Vienna, Austria. Founded in 1984, recombinant protein expression in E. coli has been Biomay’s core business from the beginning.
Today, Biomay offers cGMP services for the manufacturing of messenger RNA (mRNA), circular plasmid DNA, linear IVT-template DNA, and therapeutic recombinant proteins. Biomay operates a dedicated mRNA Competence Center for cGMP manufacturing and QC testing of mRNA drug substance and drug product (clinical and commercial).
The company’s services include process and analytical development, cell banking, R&D material supply, cGMP manufacturing, lipid nanoparticle (LNP) formulation, and aseptic fill-finish. Biomay’s manufacturing facilities are inspected by the U.S. FDA.
Contact:
Dr. Angela Neubauer, Senior Vice President Client Business; request@biomay.com
Biomay AG, Ada Lovelace-Str. 2, A-1220 Vienna, Austria; www.biomay.com
See more details on our webshop.
